The Influence of Oral Semaglutide for Vascular Inflammation in Japanese Patients with Type 2 Diabetes -INNOVATION Study - INNOVATION Study

Tahara Nobuhiro0 个研究点目标入组 60 人开始时间: 2022年7月25日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1) Patients with type 2 diabetes and a glycated hemoglobin level of 7% or more
•2) Age of 18 to 90 years at screening and written informed consent to participate in this study
•3) Age of less than 60 years with established cardiovascular disease, or age of 60 years or more with at least one cardiovascular risk factor
•4) Oral hypoglycemic agents, lipid lowering agents, antihypertensive agents, and antiplatelet agents and doses of them unchanged within 90 days prior to screening
•5) No treatment with any incretin-based antidiabetic agents (DPP-4 inhibitors or GLP-1 receptor agonists) within 90 days prior to screening

•1. Patients with diabetic ketoacidosis or hyperglycemic hyperosmolar state
•2. Patients with severe infection or surgical emergency
•3. Patients with a history of hypersensitivity to study drugs
•4. Pregnant patients
•5. Patients with significant hepatic disorders or liver cirrhosis
•6. Patients with a history of stomach resection
•7. Patients with a fasting plasma glucose level of 200 mg/dL or more
•8. Patients treated with insulin therapy
•9. Patients with malignant neoplasms
•10. Patients with active inflammatory diseases
•11. Patients judged to be inappropriate to participate in this study by investigators
•12. Patients treated with a DPP-4 inhibitor or a GLP-1 receptor agonist within 90 days before screening

发起方

Tahara Nobuhiro